Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

Summary: Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects of tocilizumab in patients with COVID-19 ar...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Sinisa Savic, Ivor S. Douglas, Julia Garcia-Diaz, Mariam S. Aziz, Nichola Cooper, Taryn Youngstein, Lorenzo Del Sorbo, David J. De La Zerda, Andrew Ustianowski, Antonio Cubillo Gracian, Kevin G. Blyth, Jordi Carratalà, Bruno François, Thomas Benfield, Derrick Haslem, Paolo Bonfanti, Cor H. van der Leest, Nidhi Rohatgi, Lothar Wiese, Charles Edouard Luyt, Rebecca N. Bauer, Fang Cai, Ivan T. Lee, Balpreet Matharu, Louis Metcalf, Steffen Wildum, Emily Graham, Larry Tsai, Min Bao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2022-05-01
coleção:	EClinicalMedicine
Assuntos:	Coronavirus disease 2019 Interleukin-6 Randomised controlled trial Tocilizumab Severe acute respiratory syndrome coronavirus-2 Viral load
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537022001390
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!